Structural analysis of human KDM5B guides histone demethylase inhibitor development

X-ray crystallographic analyses of KDM5B provide a view of the enzyme's iron( II )- and 2-oxoglutarate-containing catalytic core, and structures of KDM5B complexes with small-molecule inhibitors reveal selectivity profiles for multiple compound chemotypes. Members of the KDM5 (also known as JAR...

Full description

Saved in:
Bibliographic Details
Published inNature chemical biology Vol. 12; no. 7; pp. 539 - 545
Main Authors Johansson, Catrine, Velupillai, Srikannathasan, Tumber, Anthony, Szykowska, Aleksandra, Hookway, Edward S, Nowak, Radoslaw P, Strain-Damerell, Claire, Gileadi, Carina, Philpott, Martin, Burgess-Brown, Nicola, Wu, Na, Kopec, Jola, Nuzzi, Andrea, Steuber, Holger, Egner, Ursula, Badock, Volker, Munro, Shonagh, LaThangue, Nicholas B, Westaway, Sue, Brown, Jack, Athanasou, Nick, Prinjha, Rab, Brennan, Paul E, Oppermann, Udo
Format Journal Article
LanguageEnglish
Published New York Nature Publishing Group US 01.07.2016
Nature Publishing Group
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:X-ray crystallographic analyses of KDM5B provide a view of the enzyme's iron( II )- and 2-oxoglutarate-containing catalytic core, and structures of KDM5B complexes with small-molecule inhibitors reveal selectivity profiles for multiple compound chemotypes. Members of the KDM5 (also known as JARID1) family are 2-oxoglutarate- and Fe 2+ -dependent oxygenases that act as histone H3K4 demethylases, thereby regulating cell proliferation and stem cell self-renewal and differentiation. Here we report crystal structures of the catalytic core of the human KDM5B enzyme in complex with three inhibitor chemotypes. These scaffolds exploit several aspects of the KDM5 active site, and their selectivity profiles reflect their hybrid features with respect to the KDM4 and KDM6 families. Whereas GSK-J1, a previously identified KDM6 inhibitor, showed about sevenfold less inhibitory activity toward KDM5B than toward KDM6 proteins, KDM5-C49 displayed 25–100-fold selectivity between KDM5B and KDM6B. The cell-permeable derivative KDM5-C70 had an antiproliferative effect in myeloma cells, leading to genome-wide elevation of H3K4me3 levels. The selective inhibitor GSK467 exploited unique binding modes, but it lacked cellular potency in the myeloma system. Taken together, these structural leads deliver multiple starting points for further rational and selective inhibitor design.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1552-4450
1552-4469
DOI:10.1038/nchembio.2087